Highlights of the PMIO 2021 summit, focusing on CGT, targeted new drug & antibody drug development, the precision drug developer conference you must pay attention to

Conference introduction

From laboratory to industrialization, accelerate the realization of breakthroughs and leaps from basic research to industrial applications

Under the special background of the global post-epidemic era, the pharmaceutical industry, as a strong anti-cyclical industry, has increasingly prominent advantages

In the era of accumulating precision medicines, the crowds are competing.

On August 20-21, 2021, the 4th China Precision Medicine and Tumor Immunotherapy Summit of PMIO 2021 kicked off in Zhangjiang, Shanghai, inviting more than 600 leaders and decision makers from Top-level well-known/multinational pharmaceutical companies in the industry.

This conference will focus on the current hot topics of biotherapeutic innovation in China, from the perspectives of innovative drug development, tumor microenvironment, bispecific antibodies, ADC drugs, CGT process development and quality control, and the industrial development of CAR-T immunotherapy.

Conference covers

The conference covers areas: cell therapy, gene therapy, innovative therapies, oncolytic viruses, CDMO, CRO, regulations, IND applications, GLP, clinical trial design, GMP, immunomodulation, viral vectors, high-throughput screening, transfection, combination therapy , the IVD, digital PCR, CRISPR / CAS9 gene editor, humanized animal model, the mRNA tumor vaccine, Nanobodies, BsAbs, tumor microenvironment, stem cell therapies, recombinant proteins and the like

Conference features

● 100+ participating organizations

Wonderful review of the past

Stay tuned for more exciting PMIO China 2021 summit!